Works matching Paclitaxel

Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer

    Published in:
    Oncologist, 2019, v. 24, n. 11, p. e1024, doi. 10.1634/theoncologist.2017-0664
    By:
    • Ciruelos, Eva;
    • Apellániz‐Ruiz, María;
    • Cantos, Blanca;
    • Martinez‐Jáñez, Noelia;
    • Bueno‐Muiño, Coralia;
    • Echarri, Maria‐Jose;
    • Enrech, Santos;
    • Guerra, Juan‐Antonio;
    • Manso, Luis;
    • Pascual, Tomas;
    • Dominguez, Cristina;
    • Gonzalo, Juan‐Francisco;
    • Sanz, Juan‐Luis;
    • Rodriguez‐Antona, Cristina;
    • Sepúlveda, Juan‐Manuel
    Publication type:
    Article
    24
    25

    Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting.

    Published in:
    Wiener Klinische Wochenschrift, 2010, v. 122, n. 21/22, p. 649, doi. 10.1007/s00508-010-1483-1
    By:
    • Petru, Edgar;
    • Reinthaller, Alexander;
    • Angleitner-Boubenizek, Lukas;
    • Schauer, Christian;
    • Zeimet, Alain;
    • Dirschlmayer, Wolfgang;
    • Medl, Michael;
    • Stummvoll, Wolfgang;
    • Sevelda, Paul;
    • Marth, Christian
    Publication type:
    Article
    26
    27
    28
    29

    Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 4, p. 684, doi. 10.1007/s10147-022-02114-y
    By:
    • Nakasya, Akio;
    • Hagiwara, Yuya;
    • Ikoma, Tatsuki;
    • Kurioka, Yusuke;
    • Matsumoto, Toshihiko;
    • Yamamoto, Yoshiyuki;
    • Tsuduki, Takao;
    • Kajiwara, Takeshi;
    • Moriwaki, Toshikazu;
    • Nishina, Tomohiro;
    • Yamashita, Natsumi;
    • Hyodo, Ichinosuke
    Publication type:
    Article
    30
    31
    32

    Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3871, doi. 10.1007/s00432-022-04276-8
    By:
    • Zhang, Xin;
    • Wang, Jiandong;
    • Fan, Yali;
    • Zhao, Ziyi;
    • Paraghamian, Sarah E.;
    • Hawkins, Gabrielle M.;
    • Buckingham, Lindsey;
    • O'Donnell, Jillian;
    • Hao, Tianran;
    • Suo, Hongyan;
    • Yin, Yajie;
    • Sun, Wenchuan;
    • Kong, Weimin;
    • Sun, Delin;
    • Zhao, Luyu;
    • Zhou, Chunxiao;
    • Bae-Jump, Victoria L.
    Publication type:
    Article
    33
    34
    35
    36

    Safety profile of Paclitaxel.

    Published in:
    International Journal of Pharmacy & Life Sciences, 2015, v. 6, n. 1, p. 4177
    By:
    • Kaur Saharan, Harleen;
    • Das, Sanjita;
    • Varshney, Paresh
    Publication type:
    Article
    37
    38

    Paclitaxel- or sirolimus-coated balloons used for ArterioVEnous fistulas-2 (PAVE-2): study protocol for a randomised controlled trial to determine the efficacy of paclitaxel- or sirolimus-coated balloons in arteriovenous fistulas used for haemodialysis.

    Published in:
    Trials, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s13063-024-08502-1
    By:
    • Karunanithy, Narayan;
    • Norton, Sam;
    • Calder, Francis;
    • Das, Neelanjan;
    • Dooley, Niamh;
    • Hakobyan, Lusine;
    • Jones, Robert;
    • Padayache, Soundrie;
    • Spriggs, Chloe;
    • Steiner, Kate;
    • Suckling, Rebecca;
    • Robson, Michael G.
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45

    Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

    Published in:
    Oncologist, 2017, v. 22, n. 11, p. 1301, doi. 10.1634/theoncologist.2017-0052
    By:
    • Martín, Miguel;
    • Chacón, José I.;
    • Antón, Antonio;
    • Plazaola, Arrate;
    • García‐Martínez, Elena;
    • Seguí, Miguel A.;
    • Sánchez‐Rovira, Pedro;
    • Palacios, José;
    • Calvo, Lourdes;
    • Esteban, Carmen;
    • Espinosa, Enrique;
    • Barnadas, Agusti;
    • Batista, Norberto;
    • Guerrero, Angel;
    • Muñoz, Montserrat;
    • Romio, Estefania;
    • Rodríguez‐Martín, César;
    • Caballero, Rosalía;
    • Casas, María I.;
    • Rojo, Federico
    Publication type:
    Article
    46

    Prognostic Factors ofSurvival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer.

    Published in:
    Oncologist, 2015, v. 20, n. 2, p. 143, doi. 10.1634/theoncologist.2014-0394
    By:
    • Tabernero, Josep;
    • Chiorean, E. Gabriela;
    • Infante, Jeffrey R.;
    • Hingorani, Sunil R.;
    • Ganju, Vinod;
    • Weekes, Colin;
    • Scheithauer, Werner;
    • Ramanathan, Ramesh K.;
    • Goldstein, David;
    • Penenberg, Darryl N.;
    • Romano, Alfredo;
    • Ferrara, Stefano;
    • Von Hoff, Daniel D.
    Publication type:
    Article
    47
    48
    49
    50